Medical News Feed
German Drug Data (Deutsch)
Norwegian Drug Data (Norge)
Netherlands Drug Data (Nederlands)
Swedish Drug Data (Sverige)
Want to submit or suggest content for the epgonline.org YouTube Clinical channel?
Contact us here
epgonline.org is not responsible for content on any 3rd party website
Please register to access disease diagnosis, patient management, physician tools.
By viewing the content of this web page you are both confirming your status as a healthcare professional and agreeing to our terms of use.
| Drug class description : | Podophyllotoxin derivatives (antineoplastic agents). |
| Generic Name : | Etoposide |
| Drug description : | Vepesid Capsules: pink gelatin capsules. Vepesid Injection: vials. |
| Presentation : | Vepesid Capsules: Etoposide 50 mg , 100 mg Vepesid Injection: Etoposide 20 mg per mL. |
| Indications : | Present data indicate that Vepesid is applicable in the therapy of small cell lung cancer and resistant non-seminomatous testicular carcinoma. |
| Adult Dosage : | Oral The effective oral dose is approximately twice the effective intravenous dose, rounded to the nearest 50 mg. The usual dose for VEPESID administered orally is 100-200 mg/m2/day, days 1 to 5 or 200 mg/m2/day, days 1, 3 and 5 every 3 to 4 weeks in combination with other drugs approved for use in the disease to be treated. Dosage should be modified to take into account the myelosuppressive effects of other drugs in the combination or the effects of prior X-ray therapy or chemotherapy which may have compromised bone marrow reserve. Capsules should be taken on an empty stomach. Intravenous The usual dose for VEPESID is 50 to 100 mg/m2/day, days 1 to 5 or 100 mg/m2, days 1, 3 and 5 every 3 to 4 weeks in combination with other drugs approved for use in the disease to be treated. Dosage should be modified to take into account the myelosuppressive effects of other drugs in the combination or the effects of prior X-ray therapy or chemotherapy which may have compromised bone marrow reserve. Administration Precautions As with other potentially toxic compounds, caution should be exercised in handling and preparing the solution of VEPESID. Skin reactions associated with accidental exposure to VEPESID may occur. The use of gloves is recommended. If VEPESID solution contacts the skin or mucosa, immediately wash the skin or mucosa thoroughly with soap and water. GREAT CARE SHOULD BE TAKEN TO ENSURE THAT THE CATHETER (INFUSION) REMAINS IN THE VEIN DURING VEPESID ADMINISTRATION BECAUSE OF POSSIBLE TISSUE IRRITATION. VEPESID MUST NOT BE ADMINISTERED INTRA-ARTERIALLY, INTRA-PLEURALLY OR INTRAPERITONEALLY. Preparation for Intravenous Administration VEPESID injection may be diluted with either 5 % Dextrose Injection or 0,9 % Sodium Chloride Injection to give a final concentration of 0,2 or 0,4 mg/mL. More concentrated solutions show crystal formation upon stirring or seeding within 5 minutes and should not be given intravenously. VEPESID diluted to 0,4 mg/mL and administered through tubing connected to a pump with a peristaltic mechanism may precipitate out of solution in the tubing. Hypotension following rapid intravenous administration has been reported, hence, it is recommended that the VEPESID solution be administered over a 30 to 60 minute period. VEPESID SHOULD NOT BE GIVEN BY RAPID INTRAVENOUS PUSH |
| Child Dosage : | Not recommended. |
| Contra Indications : | Severe hepatic dysfunction. Demonstrated hypersensitivity to etoposide. Pregnancy and lactation. |
| Special Precautions : | Should be administered by individuals experienced in the use of antineoplastic therapy. See data sheet. |
| Interactions : | None stated. |
| Adverse Reactions : | Leucopenia, thrombocytopenia. Rarely, anaemia. Alopecia. Nausea and vomiting. See data sheet. |
| Manufacturer : | Bristol-Myers Squibb |
| Drug Availability : | (POM) |
Only registered users have access to the full EPG Online Knowledge Base including drug search tools, interactive disease Knowledge Centres via the EPG Knowledge Library - with clinical and evidence based physician and research tools, MiMedia (build your own clinical media collection with everything from key opinion leader essays to mode of action videos and other multi-media content), the EPG Survey panel, health news updates and much much more.
Already Registered?
Please log-in now using our member login box.
Not a member?
Don't worry, registration is quick and FREE! We welcome all Healthcare professionals, doctors, nurses and medical students.
Register today to have full access to a wealth of drug data, educational and evidence based interactive guides across all major therapeutic areas, disease management, and clinical tools.
As a practicing Healthcare professional, you can also opt-in to join our market research panel – www.epgsurvey.com – and get paid for sharing your expert clinical opinions!
REGISTER today it only takes a minute! and it's FREE
Having problems?
Use our forgotten password facility or email us at: contact@epgonline.org